Nontuberculous Mycobacterium infection and tumor necrosis factor-α antagonists

Emerging Infectious Diseases

Volumn 15, Issue 10, 2009, Pages 1700-1701

  Swart, Reinout M ^a   Van Ingen, Jakko ^b   Van Soolingen, Dick ^b   Slingerland, Rob ^a   Hendriks, Willem D H ^a   Den Hollander, Jan G ^a  

^a Maasstad Hospital Rotterdam   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMIKACIN; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; METHOTREXATE; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; BACTERIUM IDENTIFICATION; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LETTER; LYMPH NODE BIOPSY; MYCOBACTERIOSIS; MYCOBACTERIUM HAEMOPHILUM; NONHUMAN; NUCLEOTIDE SEQUENCE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; DRUG ANTAGONISM; ISOLATION AND PURIFICATION; MICROBIOLOGY;

AGED; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; METHOTREXATE; MYCOBACTERIUM HAEMOPHILUM; MYCOBACTERIUM INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349973086     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1510.090110     Document Type: Letter

References (10)

1. Saubolle MA, Kiehn TE, White MH, Rudinsky MF, Armstrong D. Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev. 1996;9:435-447
2. Lindeboom JA, Prins JM, Bruijnesteijn van Coppenraet ES, Lindeboom R, Kuijper EJ. Cervicofacial lymphadenitis in children caused by Mycobacterium haemophilum. Clin Infect Dis. 2005;41:1569-1575 DOI: 10.1086/497834
3. Shah MK, Sebti A, Kiehn TE, Massarella SA, Sepkowitz KA. Mycobacterium haemophilum in immunocompromised patients. Clin Infect Dis. 2001;33:330-337 DOI: 10.1086/321894
4. Kamboj M, Louie E, Kiehn T, Papanicolaou G, Glickman M, Sepkowitz K. Mycobacterium haemophilum infection after alemtuzumab treatment. Emerg Infect Dis. 2008;14:1821-1823 DOI: 10.3201/eid1411.071321
5. van Klingeren B, Dessens-Kroon M, van der Laan T, Kremer K, van Soolingen D. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J Clin Microbiol. 2007;45:2662-2668 DOI: 10.1128/JCM.00244-07
6. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45. DOI: 10.1002/art.10697 (Pubitemid 36091645)
7. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNFalpha treatment. Thorax. 2005;60:800-805 DOI: 10.1136/thx.2005.046797
8. van Ingen J, Boeree MJ, Dekhuijzen PN, van Soolingen D. Mycobacterial disease in patients with rheumatic disease. Nat Clin Pract Rheumatol. 2008;4:649-656 DOI: 10.1038/ncprheum0949
9. Griffith DE, Aksamit T, Brown-Elliot BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416. DOI: 10.1164/rccm.200604-571ST (Pubitemid 46271561)
10. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-784 DOI: 10.1002/ art.23721